PRAXBIND is a humanized monoclonal antibody fragment (Fab) indicated in patients treated with PRADAXA when reversal of the anticoagulant effects of dabigatran is needed:
The recommended dose of PRAXBIND is 5 g, provided as two separate vials, each containing 2.5 g/50 mL of PRAXBIND.
Ready to use immediately.
Hang vials and administer as two consecutive infusions
Inject both vials consecutively via syringe
PRADAXA can be re-initiated after 24 hours following PRAXBIND administration.
PRAXBIND is a humanized monoclonal antibody fragment (Fab) that specifically binds to dabigatran and its acylglucuronide metabolites and reverses their anticoagulant effect immediately after administration.
The most frequently reported adverse reactions in ≥5% of patients were constipation (7%) and nausea (5%).
Inform patients that reversing dabigatran therapy exposes them to the thromboembolic risk of their underlying disease. To reduce this risk, resumption of anticoagulant therapy should be considered as soon as the patient is sufficiently stable.
Inform patients to get immediate medical attention for any signs or symptoms of bleeding.
Inform patients of signs and symptoms of allergic hypersensitivity reactions such as anaphylactoid reactions that may be experienced during or after injection of PRAXBIND.
Inform patients with hereditary fructose intolerance (HFI) that PRAXBIND contains sorbitol. Parenteral administration of sorbitol in patients who have HFI has been associated with reports of hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, acute liver failure with breakdown of excretory and synthetic function, and death and may occur during or after injection of PRAXBIND.
For complete information on the pharmacokinetics of PRAXBIND, please see the Prescribing Information.
No dose adjustment is required in renally‑impaired patients.
Search our database to locate a facility in your area that has PRAXBIND available:
Please click here for the latest information on how to order PRAXBIND.
The Boehringer Ingelheim Pharamaceuticals, Inc. Return Goods Policy for PRAXBIND applies to products purchased from an Authorized Distributor of Record (ADR) that is duly licensed as a provider to dispense BIPI product. Please contact BI Customer Service at (800) 243‑0127 for additional details.
Praxbind® (idarucizumab) is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
CL-PB-100001 April 2018
Please click here for full Prescribing Information for PRAXBIND.